BioSpace News Archive

TransThera, a clinical-stage biopharmaceutical company dedicated to innovating differentiated drugs globally, today announced the initiation of IND-enabling studies for TT-02332, a potent, selective and highly CNS-penetrating NLRP3 inflammasome inhibitor.

Avadel Pharmaceuticals plc (Nasdaq: AVDL) announced today that it will host a conference call and live webcast at 7:30 a.m. ET on Monday, March 4, 2024, to provide a corporate update and discuss the Company’s financial results for the fourth quarter and full year ended December 31, 2023.

NewAmsterdam Pharma Company N.V., a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease with elevated low-density lipoprotein cholesterol, for whom existing therapies are not sufficiently effective or well-tolerated, announced that company management will participate in three upcoming investor conferences.

Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today reported financial results and key business updates for the fourth quarter and year ending December 31, 2023.

Tempest Therapeutics, Inc. announced that Stephen Brady, president and chief executive officer of Tempest, will present at the 44th Annual TD Cowen Healthcare Conference on Monday, March 4, 2024 at 9:10 a.m. ET.

Akili Announces Positive Results from Shionogi’s Phase 3 Clinical Trial of Localized Version of Akili’s EndeavorRx® for Pediatric ADHD Patients in Japan.

Nusano, a physics company transforming the production of medical radioisotopes, today announced it will participate in a presentation and panel at the B. Riley Securities Radiopharma Investor Conference in New York City on Friday, March 1, 2024.

NGM Biopharmaceuticals, Inc. announced that it has entered into a definitive Agreement and Plan of Merger under which Atlas Neon Parent, Inc. and Atlas Neon Merger Sub, Inc. will acquire NGM Bio through a cash tender offer to be commenced by Merger Sub for all outstanding shares of NGM Bio not held by affiliates of The Column Group, LP and certain other stockholders, as described below, at a price per share of $1.55 in cash.

Cadrenal Therapeutics, Inc. today announced its participation at the upcoming Technology and Heart Failure Therapeutics Conference (THT 2024), which is produced by the Cardiovascular Research Foundation (CRF), taking place March 4-6, 2024 in Boston.

Outset Medical, Inc. today announced that members of management will present at the 44th annual TD Cowen Health Care conference on Tuesday, March 5, 2024, at 1:30 p.m. Eastern time.